{"disease":{"id":"radiation-induced-nausea-and-vomiting","name":"radiation induced nausea and vomiting"},"drugs":{"marketed":[{"drug_id":"estrone","indication_name":"Prevention of Radiation-Induced Nausea and Vomiting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estron","generic_name":"ESTRONE","company_name":"Watson Labs","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"estrone","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"gran","indication_name":"Prevention of Radiation-Induced Nausea and Vomiting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GRAN®","company_name":"EVIVE Biotechnology","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 2","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ondansetron","indication_name":"Prevention of Radiation-Induced Nausea and Vomiting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zofran","generic_name":"ondansetron","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1","drug_class":"5-HT3 receptor antagonist (antiemetic)","quality_score":null,"revenue":null,"mechanism":"Selective 5-HT3 receptor antagonist that blocks serotonin-mediated nausea and vomiting signals in the CTZ and vagal afferents."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05564286","title":"Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Shantou University Medical College","has_results":false},{"nct_id":"NCT02991456","title":"Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Duke University","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}